The Lancet Gastroenterology & Hepatology
Fecha de publicación: 14 February 2020
Autores: Ola Olén, MD., Rune Erichsen, MD., Michael C Sachs, PhD.,
Prof Lars Pedersen, PhD., Prof Jonas Halfvarson, MD., Prof Johan Askling, MD., et al.
Background: Crohn’s disease is a risk factor for colorectal cancer (CRC). However, available studies reflect older treatment and surveillance strategies, and most have assessed risks for incident CRC without taking surveillance and lead-time bias into account. Such biases can be accounted for by assessing CRC incidence by tumour stage and CRC mortality by tumour stage. We aimed to assess rates of incident CRC and CRC mortality among patients with Crohn’s disease compared with the general population.Leer más